Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Tuesday's Bonus Article A Fresh IPO That Long-Term Investors Shouldn't IgnoreWritten by Jordan Chussler. Date Posted: 1/14/2026. 
Article Highlights - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Companies go public almost every week, and a handful often offer considerable short-term upside potential. Of course, IPOs can carry substantial downside risk. Still, even conservative investors might find recently listed stocks that merit a place in buy-and-hold portfolios. The Fed just flipped the switch for crypto
The biggest wealth transfer in crypto history about to begin. Click here to see more That could be the case for one biotechnology company in the healthcare sector that just went public. Last Year's IPO Success Stories Last year provides a good example of why newly listed companies shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its roughly 359% gain before it reached 30 days on the Nasdaq, but those who held on are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are all high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—famous for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% ($1 per share annually), making it an immediate consideration for income investors. Following its IPO and with shares beginning trading on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a branch of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized doses of radiation, minimizing harm to healthy tissue that could be affected by conventional radiation therapies. According to industry consultancy Grand View Research, the global nuclear medicine market was estimated at nearly $18 billion in 2024 and is forecast to reach almost $35 billion by 2030, a compound annual growth rate (CAGR) of about 10.16%. For Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after funding shifts in 2025 notably slowed healthcare listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and generated one of the larger recent raises for the sector. With $318 million raised in the offering, the firm has a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes experts in drug development, approval and commercialization, and members of management have participated in bringing 14 currently FDA-approved products to market. Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer therapies that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Notably, Aktis is clinical-stage and pre-revenue, but that did not deter Eli Lilly (NYSE: LLY) from anchoring its IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares as part of the offering. This builds on a 2024 partnership between the companies to develop tumor-targeting radiopharmaceuticals: Lilly committed $60 million in cash and an equity investment, and the agreement includes potential milestone payments that could exceed $1 billion. At roughly $1.01 trillion, Eli Lilly is one of the largest pharma companies by market cap. Its net income jumped nearly 109% year over year from 2023 to 2024, and investors will be watching its Q4 and full-year 2025 results when they are reported on Feb. 5. Between its equity stake and the $100 million purchase of AKTS shares, the maker of Zepbound now has a meaningful financial interest in Aktis' success.
| 
